Advancing Medicines for Hormone Driven Cancers

Hormone receptor positive (HR+) cancers, including ovarian, endometrial (uterine), and breast result in over 75,000 deaths per year in the United States. Antihormonals and chemotherapies are still the most common therapies used to treat these cancers. There is a need for new therapies with improved efficacy and tolerability.

Lead Program

Apristor is an investigational medicine for ovarian, uterine (endometrial), and breast cancers. These cancers are progesterone-dependent and Apristor functions by blocking the progesterone receptor (PR).

Learn more

Apristor for Ovarian Cancer

Rare Gynecological Cancers

Ovarian and endometrial cancers are comprised of several subtypes based on biophysical and molecular determinants. Subtypes that respond to progesterone signaling are typically rare and are often associated with worse prognosis.

Learn more

Apristor for Breast Cancer

Breast Cancer

In 50-70% of breast cancer patients, progesterone receptor (PR) signaling is upregulated, leading to worse outcomes for patients. In addition, PR signaling has been identified as a key resistance mechanism to current therapies.

Learn more

Our Values

GREATNESS

GREATNESS

RESPECT

RESPECT

INTEGRITY

INTEGRITY

TEAMWORK

TEAMWORK

 
latest news
 
twitter